JAHA:急性冠状动脉综合征患者血栓抽吸的应用情况

2022-08-19 MedSci原创 MedSci原创

在ST段抬高型心肌梗死患者中,TA使用与较高的PCI成功率相关,且不影响患者住院死亡率。然而,在适应症不太明确的情况下(如非st段抬高型心肌梗死和不稳定型心绞痛)应谨慎使用。

在接受经皮冠状动脉介入治疗(PCI)的患者中,血栓抽吸(TA)的使用存在显著的地域或机构差异。近日,心血管疾病领域权威杂志JAHA上发表了一篇研究文章,研究人员通日本PCI登记中心调查了急性冠状动脉综合征患者TA使用的时间趋势及其与临床结局之间的关系。

在2016年至2018年期间,接受PCI的急性冠状动脉综合征患者(n=282606;中位年龄为71.0岁;四分位差范围为62.0-79.0年;根据是否实施TA(TA和非TA)对1124家医院的女性患者(24.7%)进行了分层。根据临床表现对患者进行细分(ST-抬高段心肌梗死、非ST-抬高段心肌梗死和不稳定型心绞痛)。成功的PCI评估依据是达到心肌梗死溶栓(TIMI)3级流量和住院死亡率。

在研究期间,84322例(29.5%)患者接受了TA治疗(ST段抬高型心肌梗死、非ST段抬高型心肌梗死和不稳定型心绞痛患者分别为52.9%、23.5%和5.2%),TA实施率始终保持相对稳定。接受TA治疗的患者PCI成功率高于未接受TA治疗的患者(98.7% vs. 97.8%;P<0.001)。TA与ST段抬高型心肌梗死患者的住院死亡无关(调整比值比[aOR]为1.02[95%CI为0.94-1.12])。然而,在非ST段抬高型心肌梗死(aOR为1.51[95%CI为1.23-1.86])或不稳定型心绞痛(aOR为1.95[95%CI为1.37-2.79])患者中,使用TA与较高的住院死亡率相关。

由此可见,在ST段抬高型心肌梗死患者中,TA使用与较高的PCI成功率相关,且不影响患者住院死亡率。然而,在适应症不太明确的情况下(如非st段抬高型心肌梗死和不稳定型心绞痛)应谨慎使用。

原始出处:

Taku Inohara.et al.Use of Thrombus Aspiration for Patients With Acute Coronary Syndrome: Insights From the Nationwide J‐PCI Registry.JAHA.2022.https://www.ahajournals.org/doi/full/10.1161/JAHA.122.025728

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1641505, encodeId=a8ce164150523, content=<a href='/topic/show?id=2ac589111f5' target=_blank style='color:#2F92EE;'>#血栓抽吸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89111, encryptionId=2ac589111f5, topicName=血栓抽吸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=975022829100, createdName=12498ca5m90暂无昵称, createdTime=Mon Mar 27 21:06:09 CST 2023, time=2023-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706891, encodeId=c1511e068914c, content=<a href='/topic/show?id=15bd30902cc' target=_blank style='color:#2F92EE;'>#冠状动脉综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30902, encryptionId=15bd30902cc, topicName=冠状动脉综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=345831322662, createdName=124985dbm16(暂无昵称), createdTime=Sun Dec 04 23:06:09 CST 2022, time=2022-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268887, encodeId=66aa126888eaf, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Aug 20 11:06:09 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1432369, encodeId=d7d714323693c, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Aug 20 11:06:09 CST 2022, time=2022-08-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1641505, encodeId=a8ce164150523, content=<a href='/topic/show?id=2ac589111f5' target=_blank style='color:#2F92EE;'>#血栓抽吸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89111, encryptionId=2ac589111f5, topicName=血栓抽吸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=975022829100, createdName=12498ca5m90暂无昵称, createdTime=Mon Mar 27 21:06:09 CST 2023, time=2023-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706891, encodeId=c1511e068914c, content=<a href='/topic/show?id=15bd30902cc' target=_blank style='color:#2F92EE;'>#冠状动脉综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30902, encryptionId=15bd30902cc, topicName=冠状动脉综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=345831322662, createdName=124985dbm16(暂无昵称), createdTime=Sun Dec 04 23:06:09 CST 2022, time=2022-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268887, encodeId=66aa126888eaf, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Aug 20 11:06:09 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1432369, encodeId=d7d714323693c, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Aug 20 11:06:09 CST 2022, time=2022-08-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1641505, encodeId=a8ce164150523, content=<a href='/topic/show?id=2ac589111f5' target=_blank style='color:#2F92EE;'>#血栓抽吸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89111, encryptionId=2ac589111f5, topicName=血栓抽吸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=975022829100, createdName=12498ca5m90暂无昵称, createdTime=Mon Mar 27 21:06:09 CST 2023, time=2023-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706891, encodeId=c1511e068914c, content=<a href='/topic/show?id=15bd30902cc' target=_blank style='color:#2F92EE;'>#冠状动脉综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30902, encryptionId=15bd30902cc, topicName=冠状动脉综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=345831322662, createdName=124985dbm16(暂无昵称), createdTime=Sun Dec 04 23:06:09 CST 2022, time=2022-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268887, encodeId=66aa126888eaf, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Aug 20 11:06:09 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1432369, encodeId=d7d714323693c, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Aug 20 11:06:09 CST 2022, time=2022-08-20, status=1, ipAttribution=)]
    2022-08-20 zhaohui6731
  4. [GetPortalCommentsPageByObjectIdResponse(id=1641505, encodeId=a8ce164150523, content=<a href='/topic/show?id=2ac589111f5' target=_blank style='color:#2F92EE;'>#血栓抽吸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89111, encryptionId=2ac589111f5, topicName=血栓抽吸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=975022829100, createdName=12498ca5m90暂无昵称, createdTime=Mon Mar 27 21:06:09 CST 2023, time=2023-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1706891, encodeId=c1511e068914c, content=<a href='/topic/show?id=15bd30902cc' target=_blank style='color:#2F92EE;'>#冠状动脉综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30902, encryptionId=15bd30902cc, topicName=冠状动脉综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=345831322662, createdName=124985dbm16(暂无昵称), createdTime=Sun Dec 04 23:06:09 CST 2022, time=2022-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268887, encodeId=66aa126888eaf, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Aug 20 11:06:09 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1432369, encodeId=d7d714323693c, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Aug 20 11:06:09 CST 2022, time=2022-08-20, status=1, ipAttribution=)]

相关资讯

JAHA:急性冠状动脉综合征后病情稳定患者的心血管事件和长期猝死风险

ACS后10天内病情稳定的患者仍存在发生猝死的长期风险,其中发生额外心血管事件的风险最大。这些结果细化了猝死的长期风险和风险影响因素,这可能有助于临床医生改善治疗的机会。

JAMA Cardiol:特殊房颤患者的抗凝选择

与VKA相比,采用阿哌沙班治疗的患者的出血、死亡或住院率较低

JAMA Cardiol:急性冠状动脉综合征患者复杂PCI后采用普拉格雷降级治疗有利无害!

普拉格雷剂量降级治疗不会增加ACS患者的MACE事件风险,而且还会降低出血事件发生率。

ARD:使用生物 DMARD的RA患者队列中急性冠状动脉综合征的短期、中期和长期风险:来自四个北欧国家的结果

与一般人群相比,使用生物类疾病改善抗风湿药(bDMARDs)的类风湿性关节炎患者急性冠状动脉综合征(ACS)发生率较高。在常规护理中使用时,ACS 的短期、中期和长期风险在各bDMARD之间差别不大。

JAHA:花粉浓度的时间变化预测急性冠状动脉综合征的短期临床结局

花粉浓度增加与不同的ACS亚型无关,但与经皮冠状动脉介入治疗后的住院死亡率显著相关,强调了花粉暴露与临床结局之间的潜在生物学联系。